As a pioneer of contraceptive and reproductive health medicines, Beijing Zizhu Pharmaceutical Co., Ltd. has filled the domestic gap many times by taking the lead in developing and launching new products in the market.

l        1970  Being the first one in China to successfully carry out the trial production of norgestrel, the company has made tremendous contribution to the development of Chinese oral contraceptive and the national policy of family planning.

l        1981  The company was the first one in China to successfully develop the second generation oral contraceptive levonorgestrel and promote it in the market. This product obtained the “Second-grade Award of Beijing Science and Technology Progress”. Compound levonorgestrel reduces the side effect of oral contraceptive and has reached the international level in quality.

l        1992  The launch of Mifepristone filled the gap of abortion medicines in China. The application of abortion medicines avoids the sequelae caused by induced abortion and also alleviates physical and psychological pains of woman of childbearing age as well as their fears.

l        1998  The first emergency contraceptive levonorgestrel tablets(0.75mg) was available in the Chinese market. The launch of emergency contraceptive reduced large numbers of unwilling pregnancy and abortion rate. Levonorgestrel tablets(0.75mg) has now become the OTC emergency contraceptive with the largest sales volume in China.

l        1998 . Gestrinone, the first most effective medicine for endometriosis treatment in China, was successfully developed. It ends the situation that Chinese women depending on imported medicines for endometriosis treatment. Cheaper treatment plan with high quality were thus available to ease the pain of women suffering from this chronic and stubborn disease.

l        2002  Misoprostol Tablet was home made and launched into the market. The cost burden of patients has thus been relieved. This project won the certificate of Beijing High-tech Transferring Project.

l        2002  Tibolone tablets for menopause syndrome entered the market. This medicine once again filled the gap for Chinese gynecological medicine. Tibolone tablets is different from the traditional HRT (Hormone Replacement Therapy)£¬featuring safer, more efficient and economical treatment. This project won the award of Beijing High-tech Transfer Project Certificate.

l        2005  Low dose short acting oral contraceptive Levonorgestrel and ethinylestradiol tables was available in the market. The integrated design based on the principle of “Human Oriented” effectively avoids the failure of taking medicine and has thus provided reliable contraceptive protection for customers. By enabling women to control their menstrual cycle, this medicine is user-friendly and allows women to enjoy their lives without any burden.

l        2006  levonorgestrel tablets(1.5mg) is one-tablet package emergency contraceptive was available in the market. This medicine seeks increasing perfection and is taken only one tablet at one time, safe and convenient.

Medicines to be launched

l        2007  Compound gestodene (The third generation of short acting oral contraceptive). Having the strongest progestogen, this medicine is the most ideal short acting oral contraceptive up to now.